Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
about
Current and emerging cell culture manufacturing technologies for influenza vaccines.Molecular Characteristics of Influenza Virus Type B Lineages Circulating in Poland.Influenza immunology evaluation and correlates of protection: a focus on vaccines.Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adultsQuadrivalent influenza vaccine in the United States.Vaccination in elite athletes.An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static ModelInfluence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial.Retrospective public health impact of a quadrivalent influenza vaccine in the United States.Detection of influenza B lineages from 2001 to 2013 in a tertiary hospital in the city of São Paulo, Brazil.Systems vaccinology: Enabling rational vaccine design with systems biological approaches.Traditional and new influenza vaccinesFluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.Evaluating the case for trivalent or quadrivalent influenza vaccines.Epidemiology of influenza B in Australia: 2001-2014 influenza seasons.Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination.A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control.Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial.Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 years of age and older.Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.[Quadrivalent influenza vaccines].Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.Influenza vaccines: Evaluation of the safety profile.Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.Cell culture-derived flu vaccine: Present and future.Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
P2860
Q30373128-75AD86C1-C75B-4291-A06B-6B6B7B30CD64Q30383963-AD1CA36D-FC12-4A89-91D1-8821D5E9034CQ30385397-75A065AB-D50A-49DD-9E59-9AB0D892D208Q33609256-057F538A-4996-4ECD-B073-3065AFE84EC6Q33723445-A773D5F3-06A0-4D1F-A5C1-D5448B6AB92CQ34033810-D7072ADA-7911-4EAB-9222-34A8ABAA7992Q34227424-2A6AE50D-B1D5-4B89-BB82-3444CB067021Q35723417-6955D38F-1394-4A1F-A155-02003AE332BCQ35862144-2AAFFE3D-EDD9-4242-AE26-04BAD3755B6DQ35995259-76554EE0-22A2-48CD-A7BD-968F097E622FQ36059666-433A1FEB-D29B-4BB3-A6AD-4A2245EF84A3Q36090112-9632AB5E-FA2C-4181-BA0C-19EE374F3471Q37035833-BE3CC7D5-2D44-43DD-A392-2C460D7C7F7EQ37375954-9E65CA9F-3E00-4BD1-970C-F409B4E6F9D2Q37375959-28D4B897-1E96-4D6B-80F1-F36E2ECD4277Q37638402-F9CA9C49-5A82-4DB2-8F27-FD83C45DCE34Q38204774-EBF7716A-742B-4348-A123-7C7801ACF444Q39322780-B3FAD4AA-EA6F-443C-B1A5-89445E232EC1Q40073913-BA19505A-B5A6-46C1-8B39-74D4A6C45FBBQ40138220-A256EA41-B833-4E70-A3DC-A4A9E0C699C9Q40244064-B39B2417-3768-4C0C-9482-D9B0911A7B4CQ41389931-D547F6BA-1F6F-4D8B-8988-866C8E4CAA68Q41483739-BEF1A1AF-F248-491B-A66B-70762FE8B049Q41995736-A53CBB87-3498-4C88-BCE3-A1F9D945F805Q49345779-DC2F6FB8-4930-4923-856D-49A1806C7B00Q49965782-0B6CB1AB-26B7-4D33-9C0D-D3BB3E929F63Q50026937-9DE27266-88A2-4E87-B282-3134B1C4437EQ52315669-DBBAC74B-403C-4453-9EAF-FC3AD0D69AF6Q52579975-68F822C6-0704-4B16-A773-773A1F0D4512
P2860
Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Safety and immunogenicity of a ...... influenza vaccines in adults.
@en
Safety and immunogenicity of a ...... influenza vaccines in adults.
@nl
type
label
Safety and immunogenicity of a ...... influenza vaccines in adults.
@en
Safety and immunogenicity of a ...... influenza vaccines in adults.
@nl
prefLabel
Safety and immunogenicity of a ...... influenza vaccines in adults.
@en
Safety and immunogenicity of a ...... influenza vaccines in adults.
@nl
P2093
P1433
P1476
Safety and immunogenicity of a ...... d influenza vaccines in adults
@en
P2093
Corwin A Robertson
David P Greenberg
Mark M Blatter
Michael J Noss
Rex Biedenbender
P304
P356
10.1016/J.VACCINE.2012.11.074
P407
P577
2012-12-08T00:00:00Z